3/16
01:09 am
orka
Medium
Report
3/13
03:58 pm
orka
Oruka Therapeutics (ORKA) had its price target raised by Barclays PLC from $48.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Oruka Therapeutics (ORKA) had its price target raised by Barclays PLC from $48.00 to $50.00. They now have an "overweight" rating on the stock.
3/13
10:59 am
orka
Oruka Therapeutics (ORKA) had its "buy" rating reaffirmed by BTIG Research. They now have a $73.00 price target on the stock.
Medium
Report
Oruka Therapeutics (ORKA) had its "buy" rating reaffirmed by BTIG Research. They now have a $73.00 price target on the stock.
3/13
10:40 am
orka
Oruka Therapeutics (ORKA) had its price target raised by Stifel Nicolaus from $47.00 to $72.00. They now have a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics (ORKA) had its price target raised by Stifel Nicolaus from $47.00 to $72.00. They now have a "buy" rating on the stock.
3/12
04:42 pm
orka
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/12
04:05 pm
orka
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
High
Report
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/8
01:31 am
orka
Low
Report
2/9
08:06 am
orka
Oruka Therapeutics to Participate in Multiple Upcoming Conferences [Yahoo! Finance]
Low
Report
Oruka Therapeutics to Participate in Multiple Upcoming Conferences [Yahoo! Finance]
2/9
07:00 am
orka
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
Low
Report
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
1/13
09:02 am
orka
Oruka Therapeutics (NASDAQ:ORKA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $42.00.
Low
Report
Oruka Therapeutics (NASDAQ:ORKA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $42.00.
1/12
11:29 am
orka
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a "buy" rating on the stock.
1/12
07:20 am
orka
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]
Medium
Report
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]
1/12
07:00 am
orka
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
High
Report
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
1/9
06:10 am
orka
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/7
02:01 am
orka
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
07:00 am
orka
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
10:16 pm
orka
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears [Seeking Alpha]
Low
Report
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears [Seeking Alpha]
12/19
05:58 am
orka
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
High
Report
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
12/18
07:11 am
orka
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Low
Report
Oruka Therapeutics (NASDAQ:ORKA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.